Abstract
Background Atopic dermatitis is a common chronic pruritic inflammatory skin disease, tends to occur in children. The objective of this study is to evaluate the treatment of pediatric atopic dermatitis with Biologics, as biologics continue to emerge for atopic dermatitis (AD)
Methods The databases we will search include Embase, Cochrane Library, Web of Science, the and PubMed of RCTs from inception to 15st May 2022. The primary outcomes The proportion of patients with EASI 75 as the primary outcome,. The secondary outcomes incloud NRS, DLQI score and adverse reaction incidence.Studies will be screened by two independent authors. They will assess the risk of bias of the final included studies according to the RCTs bias risk evaluation tool in Cochrane System Review Manual 5.1.0. Meta-analysis will be performed using RevMan 5.3 software.
Results The research results will provide a reference for the clinical application of biological agents in pediatric atopic dermatitis.
Conclusion We aims to evaluate the efficacy and safety of biologics in pediatric atopic dermatitis and provide evidence-based data for clinical application
Ethics and dissemination The study does not collect raw data and personal information, does not involve jeopardizing the rights of the participants. Ethical approval was not required. The results may be reported in publications and the media
PROSPERO registration number CRD42022319052
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/PROSPERO/#joinuppage
Funding Statement
The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All study files are available from the pubmed database
Abbreviations
- AD
- atopic dermatitis;
- RCT
- randomized controlled trial;
- SMD
- Standard Mean Difference;
- RR
- risk ratio;
- CI
- confidence interval;
- EASI
- Eczema Area and Severity Index;
- DLQI
- Dermatology Life Quality Index;
- NRS
- Numerical Rating Scale.
